USP7 and ovarian carcinoma: Qin et al. (2016) have demonstrated that CDDO-Me directly binds to USP7, markedly inhibits its activity (IC50 = 14.08 μM), and induces the degradation of MDM2, MDMX, and UHRF1. CDDO-Me has also shown anticancer activity in ovarian cancer cells in vitro and in HO8910 and SKOV3 xenograft models in vivo.